Work

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Year: 2023

Type: article

Abstract: TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic. CLINICALTRIALS: gov/ct2/show/NCT05821153.

Source: Translational Neurodegeneration

DOI: 10.1186/s40035-023-00387-5

Authors: Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, Weihua Zhao, David R. Beers, Maria B. Pascual, Mohammad O. Nakawah, Gustavo C. Roman, Charles S. Davis, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel

Institutions: Houston Methodist, Houston Methodist Research Institute, Bear Valley, University of California San Diego

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,890

Funders: Alzheimer's Association, University of Texas MD Anderson Cancer Center, Houston Methodist Research Institute

Award: Regulatory T cells as a novel therapeutic target in Alzheimer's Disease

OpenAlex ID: W4388725349

FWCI: 8.834

Cites: 12

Cited by: 35

Related to: 10